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Abstract
Background. A multitude of risk/protective factors for anxiety and obsessive-compulsive dis-
orders have been proposed. We conducted an umbrella review to summarize the evidence of
the associations between risk/protective factors and each of the following disorders: specific
phobia, social anxiety disorder, generalized anxiety disorder, panic disorder, and obsessive-
compulsive disorder, and to assess the strength of this evidence whilst controlling for several
biases.
Methods. Publication databases were searched for systematic reviews and meta-analyses
examining associations between potential risk/protective factors and each of the disorders
investigated. The evidence of the association between each factor and disorder was graded
into convincing, highly suggestive, suggestive, weak, or non-significant according to a standar-
dized classification based on: number of cases (>1000), random-effects p-values, 95% predic-
tion intervals, confidence interval of the largest study, heterogeneity between studies, study
effects, and excess of significance.
Results. Nineteen systematic reviews and meta-analyses were included, corresponding to 216
individual studies covering 427 potential risk/protective factors. Only one factor association
(early physical trauma as a risk factor for social anxiety disorder, OR 2.59, 95% CI 2.17–
3.1) met all the criteria for convincing evidence. When excluding the requirement for more
than 1000 cases, five factor associations met the other criteria for convincing evidence and
22 met the remaining criteria for highly suggestive evidence.
Conclusions. Although the amount and quality of the evidence for most risk/protective fac-
tors for anxiety and obsessive-compulsive disorders is limited, a number of factors signifi-
cantly increase the risk for these disorders, may have potential prognostic ability and
inform prevention.
Introduction
Anxiety disorders are the most common group of mental disor-
ders and are associated with enormous societal costs (Kessler
et al., 2010; Craske and Stein, 2016). Both ‘genetic’ and ‘non-
genetic’ (i.e. environmental) variables (as well as their interaction)
have been proposed as potential risk/protective factors for anxiety
disorders (Craske et al., 2017), although such a distinction may be
somewhat artificial, given that many risk/protective factors
include both genetic and non-genetic components. The evidence
on risk/protective factors for anxiety disorders has been summar-
ized in several systematic reviews and meta-analyses. However,
findings are conflicting and there have been no previous attempts
to summarize in a single report the strength of the evidence for
the different potential risk/protective factors for each anxiety dis-
order or to assess possible biases in the literature.
We present the results of an umbrella review of risk/protective
factors for the most common anxiety disorders. We will focus on
specific phobia, social anxiety disorder (SAD), generalized anxiety
disorder (GAD), panic disorder (PD), and obsessive-compulsive
disorder (OCD) – the latter having been classified as an anxiety
disorder until the publication of the 5th edition of the
Diagnostic and Statistical Manual of Mental Disorders (DSM-5;
American Psychiatric Association, 2013). Umbrella reviews sys-
tematically collect and assess the existing evidence from individ-
ual studies included in systematic reviews and/or meta-analyses
and have an increasing role in evidence-based health care and
evidence-based assessments (Ioannidis, 2009; Fusar-Poli and
Radua, 2018).
In the current absence of valid biomarkers or clear mechanistic
explanations for most mental disorders (Kapur et al., 2012), the
identification of putative (and, at least for some, modifiable)
risk/protective factors may lead to the development of more effi-
cient risk prediction models, and may offer clues for prevention
and treatment (Paulus, 2015; Moreno-Peral et al., 2017;
Fusar-Poli et al., 2018). Our aim was to systematically assess the
amount of evidence and the robustness of associations between
potential risk/protective factors and each of the aforementioned
disorders.
Methods
We conducted an umbrella review (Ioannidis, 2009; Fusar-Poli
and Radua, 2018) to assess the relation between potential risk/
protective factors and anxiety and obsessive-compulsive disorders.
We followed the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009) and
the Meta-analysis of Observational Studies in Epidemiology
(MOOSE) guidelines (Stroup et al., 2000) (online Supplementary
Tables S1 and S2). The study protocol was pre-registered with
the International Prospective Register of Systematic Reviews
(PROSPERO; CRD42017060090).
Search strategy and eligibility criteria
We searched PubMed, Web of Science, and Scopus from inception
to April 30 2018 for systematic reviews and meta-analyses of
observational studies examining associations between potential
risk/protective factors (see below) separately for each disorder.
The search strategy used the keywords ‘systematic review’ or
‘meta-analysis’ and each of the disorders of interest. We also
hand searched the reference lists of all systematic reviews and
meta-analysis reaching full-text review.
Eligibility criteria were: (1) a systematic review or
meta-analysis of risk/protective factors for specific phobia, SAD,
GAD, PD, or OCD as defined in any edition of the
International Classification of Diseases (ICD) manual or the
DSM; (2) inclusion of a healthy comparison group; and (3) stud-
ies reporting sufficient data (or that were retrievable after contact-
ing the authors) to perform the analyses. We did not apply any
language restrictions in the selection of systematic reviews or
meta-analyses.
Even though we had hoped to include molecular genetic stud-
ies in the umbrella review, we found that the literature for the dis-
orders investigated is dominated by candidate gene studies, which
are known to have low credibility. Such risk factor assessment
should await thus the publication of large genome-wide studies
(Ioannidis et al., 2008). Moreover, different analytical methods
and assessment criteria are required for umbrella reviews of gen-
etic variables (Ioannidis et al., 2008).
Although in some DSM classifications previous to DSM-5
‘panic disorder’ and ‘panic disorder with agoraphobia’ have
been classified separately, we included both in our ‘panic disorder’
category. However, we have analyzed them separately where a
study reported separate factors for each of these categories. We
also considered separation anxiety disorder and selective mutism
(‘anxiety disorders’ in the DSM-5), but they were not included
due to the lack of systematic reviews and meta-analyses (online
Supplementary Figs S6 and S7). Posttraumatic stress disorder
(PTSD), grouped as an anxiety disorder until the publication of
DSM-5, will be covered in a separate manuscript.
Further information about the search strategy and the eligibil-
ity criteria can be found in the online Supplementary material.
Risk/protective factor definition
We used the following definition of risk factor: ‘that characteristic,
variable, or hazard preceding the outcome of interest that, if pre-
sent for a given individual, makes it more likely that this individ-
ual, rather than someone selected from the general population,
will develop a given disorder’ (Mrazek and Haggerty, 1994;
Kraemer et al., 1997). Similarly, protective factors are those
where risk is found to be decreased. We assessed both stable fac-
tors (e.g. sex), for which time precedence does not need to be
established, and factors that are subject to change within-subject.
For the latter, we required that the determination of the factor
preceded the diagnosis of the outcome (i.e. the disorder) even if
the information on the factor and the outcome was collected at
the same time point (as in the case of cross-sectional studies).
This rule ensured that there would be time precedence for the
assessments of factors and outcomes, although factors may have
existed even before their determination, and disorders may have
also existed before their diagnosis. Furthermore, when the factor
investigated was related to personality dimensions (e.g. neuroti-
cism), we also required that personality was assessed before the
disorder was diagnosed in order to avoid state-trait influences
(Reich et al., 1987). The definitions for each factor were those
given in the corresponding systematic review or meta-analysis.
Following previous work (Radua et al., 2018) we grouped factors
into several descriptive categories: sociodemographic, psychopath-
ology, parental psychopathology, personality dimensions, substance
use, life events, perinatal complications, parental rearing styles/
attachment, and others.
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Data extraction and selection
We used a systematic approach to extract and select the data. First,
we identified the factors assessed in each systematic review or
meta-analysis. Second, two investigators independently checked
that each individual article included in the systematic review or
meta-analysis met the same eligibility criteria applied to the sys-
tematic review or meta-analysis. Third, two investigators inde-
pendently extracted the following data (from the systematic
review or meta-analysis or, in most cases, from the individual
studies): first author and year of publication; number of cases
and controls; measure and size of the risk and corresponding
95% confidence intervals (CIs); specific variables depending on
the measure of effect size; and whether the study was a prospect-
ive cohort. Specific variables depending on the measure of effect
size were: number of cases and person-times in exposed and
unexposed for incidence rate ratios (IRR), number of cases and
total number of exposed and unexposed for risk ratios (RR), num-
ber of exposed and unexposed and cases and controls for odds
ratios (OR), and means and standard deviations for cases and
controls for standardized mean differences (SMD). Fourth, two
investigators independently rated the quality of the systematic
review or meta-analysis using the Assessment of Multiple
Systematic Reviews (AMSTAR; Shea et al., 2007) tool, with sub-
stantial interrater agreement (both weighted Cohen’s kappa and
intraclass correlation = 0.71; see online Supplementary material).
A third investigator reviewed the extracted data to check for
inconsistencies, and disagreements were resolved by consensus.
For further details on the data extraction, selection, and quality
assessment, see the online Supplementary material.
Statistical analysis
We performed statistical analyses commonly used in standard
meta-analyses. However, we did not use the statistics provided
in the included systematic review or meta-analyses because
there are differences across-studies in the methods employed
and because some analyses are often not conducted (e.g. the
test for an excess of significant findings).
We conducted a separate random-effects meta-analysis for
each factor and disorder. The outcomes of the meta-analyses
were the effect sizes with their CIs and p-values, and the statistics
required to assess the level of evidence (see below). Depending on
the factor, we used IRR, RR, OR, or SMD Hedges’ g. For descrip-
tive purposes, we also report OR equivalents (eOR) of IRR, RR,
and Hedge’s g (see Fusar-Poli and Radua (2018) for additional
details).
We assessed between-study heterogeneity by estimating the
95% prediction interval – which evaluates the uncertainty for
the effect that would be expected in a new study addressing that
same association – and the I2 metric (Ioannidis et al., 2007). I2
> 50% were considered to represent substantial heterogeneity
(Higgings and Green, 2009). We also assessed whether there
was evidence of small-study effects with Egger tests (Egger
et al., 1997), where statistical significance would mean potential
reporting or publication bias in the smaller studies. Finally, excess
significance (a relative excess of statistically significant findings)
was assessed with a binomial test that compared the observed v.
the expected number of studies yielding statistically significant
results (Radua et al., 2018).
The levels of evidence of the associations between each factor
suggestive (class II), suggestive (class III), or weak (class IV)
(Fusar-Poli and Radua, 2018). Convincing evidence required a
number of cases (n) >1000, a highly significant association ( p <
10−6), I2 < 50%, a statistically significant 95% prediction interval,
and the absence of small-study effects and excess significance bias.
Highly suggestive evidence also required n > 1000, a highly signifi-
cant association ( p < 10−6), and that the largest study had a stat-
istically significant effect. Suggestive evidence required n > 1000
and p < 10−3. Weak evidence required no specific number of
cases and p < 0.05. Furthermore, after collecting all the available
evidence, we noticed that, with few exceptions, there were fewer
than 1000 cases for most factors. Therefore, we also examined
these criteria removing the requirement of n > 1000, so as to
obtain a more fine-grained appraisal of the evidence. For associa-
tions with significant evidence (classes I–IV), we also conducted a
sensitivity analysis by using only prospective cohort studies.
Results
We included 19 systematic reviews and meta-analyses (Fig. 1 and
online Supplementary Figs S1–S5). AMSTAR scores are presented
in Table 1. All extracted data and results are available at: https://
www.umbrellaevidence.com/anxiety/riskfactors/.
We extracted data for 427 factors from 216 individual studies.
The number of systematic reviews and meta-analyses, individual
studies assessed and included, and factors included are presented
in Table 2. The groups of factors assessed in each systematic
review or meta-analysis are reported in Table 1 and the specific
factors in online Supplementary Table S3. Factors showing con-
vincing, highly suggestive, or suggestive evidence of association
with each disorder are presented in Table 3. All significant factors
(including those showing weak evidence of association) are pre-
sented in online Supplementary Table S4.
Overall, the number of cases was greater than 1000 for 20 fac-
tors (4.68%). One-hundred eighty-three of the 427 factors
(42.84%) presented a statistically significant effect ( p < 0.05)
under the random-effects model, but only 91 (21.31%) had a p
< 0.005 and only 27 (6.32%) reached p < 10−6. Twenty-five factors
(36.76%) presented a large estimate of heterogeneity (I2 > 50%),
while for 29 factors (78.37%) the 95% prediction interval did
not include the null. Additionally, evidence for small-study effects
and excess significance bias was noted for 2 (5.40%) and 8
(1.87%) factors, respectively (see online Supplementary Table S4).
Results by disorder
Specific phobia
No factor showed convincing or highly suggestive evidence as a
risk/protective factor for specific phobia using the original
umbrella review criteria. Removing the n > 1000 criterion, being
male showed convincing evidence as protective factor.
Moreover, neuroticism showed highly suggestive evidence as
risk factor for the disorder, which was maintained after the sen-
sitivity analyses (Table 3, Fig. 2, and online Supplementary
Table S4).
Social anxiety disorder
Early physical and sexual trauma showed, respectively, convincing
and suggestive evidence as risk factors for SAD. Additionally,
when removing the n > 1000 criterion, dysthymia, insecure attach-
ment in childhood, major depression, and neuroticism showed
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Fig. 1. Flow chart of the literature search (see online Supplementary material for the flowcharts for each specific disorder).
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sensitivity analyses, evidence for both trauma-related factors
became weak, but the rest of factors–except insecure attachment
in childhood- maintained the same level of evidence (Table 3,
Fig. 2, and online Supplementary Table S4).
Generalized anxiety disorder
No factor showed convincing or highly suggestive evidence as a
risk/protective factor for GAD. Removing the n > 1000 criterion,
being male showed convincing evidence as protective factor for
GAD and the following factors showed highly suggestive evidence
as risk factors for the disorder: psychological malaise at age 33,
borderline personality disorder, parental GAD without comorbid-
ity, early physical and sexual trauma, and behavioral inhibition
(assessed as a personality dimension). After sensitivity analyses,
all these factors – except both trauma-related variables – main-
tained the same level of evidence (Table 3, Fig. 2, and online
Supplementary Table S4).
Panic disorder
No factor showed convincing or highly suggestive evidence as
risk/protective factor for PD. Removing the n > 1000 criterion,
being male, separation anxiety in childhood, and early physical
trauma showed convincing evidence as risk/protective factors
for PD. The evidence was not maintained, however, after sensitiv-
ity analyses. Furthermore, daily cigarette smoking, panic attacks,
and major depression showed highly suggestive evidence as risk
factors for PD, which was maintained after sensitivity analyses
(Table 3, Fig. 2, and online Supplementary Table S4).
Obsessive-compulsive disorder
No factor showed convincing or highly suggestive evidence as
risk/protective factor for OCD. Removing the n > 1000 criterion,
several parental rearing style variables, neuroticism, and use of
cocaine together with another drug (except marijuana) showed
highly suggestive evidence as risk/protective factors for OCD.
Table 1. Systematic reviews and meta-analyses included in the umbrella review, quality scores, and groups of risk/protective factors examined, by disorder
Systematic review/
meta-analysis
AMSTAR score
(0–11)a Groups of risk/protective factors examined Disorders examined
Brander et al. (2016a) 6 Socio-demographic; parental rearing styles/attachment; substance use; life
events; other
OCD
Brown et al. (2000) 3 Life events Specific phobia, GAD,
PD
Clarner et al. (2015) 8 Life events PD
Clauss and Blackford
(2012)
8 Other (behavioral inhibition in childhood) SAD
Colonnesi et al. (2011) 8 Parental rearing styles/attachment SAD
Fernandes et al.
(2015)
8 Life events SAD, GAD, PD
Gariepy et al. (2010) 10 Other (obesity) GAD
Guo et al. (2016) 10 Socio-demographic Specific phobia, SAD,
GAD, PD, OCD
Jacobson and
Newman (2017)
7 Psychopathology Specific phobia, GAD,
PD
Kedzior and Laeber
(2014)
7 Substance use Specific phobia, GAD,
PD, OCD
Kisely et al. (2017) 11 Socio-demographic SAD, GAD, PD
Kossowsky et al.
(2013)
10 Psychopathology PD
Kotov et al. (2010) 5 Personality dimensions Specific phobia, SAD,
GAD, OCD
Micco et al. (2009) 7 Parental psychopathology SAD, GAD, PD, OCD
Moreno-Peral et al.
(2014)
9 Socio-demographic; psychopathology; parental psychopathology; personality
dimensions; substance use; life events; perinatal complications; parental rearing
styles/attachment; other
GAD, PD
Moylan et al. (2012) 6 Substance use Specific phobia, SAD,
GAD
Osborn et al. (2016) 8 Other (traumatic brain injury) GAD
Tarricone et al. (2012) 8 Socio-demographic GAD
Van Steensel et al.
(2011)
6 Psychopathology Specific phobia
AMSTAR, Measurement tool to assess the methodological quality of systematic reviews; GAD, generalized anxiety disorder; PD, panic disorder; OCD, obsessive-compulsive disorder; SAD,
social anxiety disorder.
Note: Some risk/protective factors were assessed only for some of the disorders included in the corresponding systematic review/meta-analysis.
The specific risk/protective factors assessed in each systematic review or meta-analysis are reported in online Supplementary Table S4.
aRounded-up average of two raters.
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However, the latter was based on a single study reporting one sin-
gle case in the exposed group. Only neuroticism and use of
cocaine together with another drug (except marijuana) main-
tained the same level of evidence after the sensitivity analyses
(Table 3, Fig. 2, and online Supplementary Table S4).
Discussion
This is, to the best of our knowledge, the first umbrella review of
risk/protective factors for anxiety and obsessive-compulsive disor-
ders. Our study provides a state-of-the-art classification of risk/
protective factors based on the robustness of associations between
these factors and five separate disorders, while controlling for sev-
eral biases.
Using the original umbrella review criteria, early physical
trauma was the single most consistent risk factor – class I – for
SAD. Early sexual trauma was also associated – class III – with
SAD. Several ‘traditional’ risk/protective factors for anxiety and
obsessive-compulsive disorders were among those that had nom-
inally statistically significant results (Beesdo et al., 2009; Craske
and Stein, 2016). Although we could not assess exactly the
same factors for all disorders, a number of factors showed a simi-
lar association with several of the disorders investigated (Fig. 3).
For example, being male was associated with decreased risk for
specific phobia, SAD, GAD, and PD; and neuroticism was asso-
ciated with increased risk for specific phobia, SAD, GAD, and
OCD. Moreover, early traumatic experiences increased the risk
of all disorders in which they were investigated (SAD, GAD,
PD, and OCD). Although the evidence for most of these associa-
tions was rated as weak, the consistency of these signals across
multiple disorders strengthens the case that they do carry prog-
nostic potential. The fact that the same factors increased the
risk for different disorders may indicate a shared liability within
anxiety and obsessive-compulsive disorders (Blanco et al.,
2014). Moreover, some factors may be shared across mental disor-
ders (i.e. be ‘transdiagnostic’). For example, early traumatic
experiences are a significant risk factor for depressive (Köhler
et al., 2018), psychotic (Belbasis et al., 2018; Radua et al., 2018),
and bipolar disorders (Bortolato et al., 2017). Importantly, the
results of our umbrella review provide hints not only on the pres-
ence/absence of a particular factor but also on the loading
(weight) of that factor, which may be still unique (Uher and
Zwicker, 2017).
The non-specificity of the findings for most risk factors inves-
tigated here (and probably for most risk factors for mental disor-
ders in general) may also be partially explained by the fact that
developmental effects (including temporal dynamics and the
development of comorbidity over time) are often ignored in cur-
rent nosological systems. The use of longitudinal ‘staging models’ –
that describe the progression from more simple or ‘pure’ disorders
to more complex or comorbid disorders – has been proposed to
deal with these issues. Such models could offer a better descrip-
tion of the developmental patterns typical to most mental disor-
ders (Beesdo et al., 2009).
Our data suggest that rather than ‘a few’ risk or protective fac-
tors with large effects, large sets of common ‘variants’ of small
effects account for the risk for anxiety and obsessive-compulsive
disorders. This idea, which is well established in psychiatry genet-
ics (Anttila et al., 2018; Sullivan et al., 2018), seems to be also true
for ‘non-purely genetic’ factors (Uher and Zwicker, 2017).
Furthermore, our findings open the door to the potential develop-
ment of enhanced risk prediction models (Bernardini et al., 2017)
and individual risk prediction scores (see Kessler et al., 2014, and
Shalev et al., 2019 for specific examples in PTSD). In recent years,
the use of polygenic risk scores has been validated in disorders
such as schizophrenia (International Schizophrenia Consortium
et al., 2009). More recently, the use of ‘poly-environmental scores’
has been proposed (Padmanabhan et al., 2017; Uher and Zwicker,
2017). Given that multiple genetic and non-genetic factors have
much greater explanatory power than considering them one at a
time in most mental disorders (Uher and Zwicker, 2017), it is
likely that ‘poly-risk’ scores (containing both genetic and non-
genetic factors) improve the prediction of mental disorders. Our
data may help developing such scores for anxiety and obsessive-
compulsive disorders, although the time of exposure and the
cumulative nature of non-genetic risk will need to be taken into
account to improve such prediction abilities (Moffitt et al.,
2005; Sharma et al., 2016). Developmental effects – and their
potential interaction with genetic variables- are difficult to study
using epidemiological data, but they could be investigated using
animal models (Leonardo and Hen, 2008).
The majority of factors were only classified as having weak evi-
dence (class IV). This mainly reflects the methodological limita-
tions of the data, where less than 5% of the factors included
more than 1000 cases and where the significance of the associa-
tions for each individual factor was overall low. The (weak)
strength of the associations found, together with limitations
inherent to the individual study designs employed to date, pre-
cludes firm causal inferences for any of the significant factors
identified in our umbrella review (Paulus, 2015). Future work to
identify risk/protective factors could focus on large-scale family-
based designs, that allow for a more stringent control of
Table 2. Number of systematic reviews and meta-analyses included in the umbrella review, individual studies assessed and included, and potential risk/protective
factors included in the umbrella review, by disorder
Disorder
Number of systematic reviews
or meta-analyses included
Number of individual
studies assessed for
eligibility
Number of individual
studies included
Number of potential risk/
protective factors included
Specific phobia 6 63 19 13
Social anxiety disorder 10 110 34 20
Generalized anxiety
disorder
13 132 57 110
Panic disorder 11 144 60 78
Obsessive-compulsive
disorder
6 160 46 206
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Table 3. Risk/protective factors showing convincing (class I), highly suggestive (class II), or suggestive (class III) evidence of association with each disorder using the original umbrella review criteria or after removing the n > 1000 cases criterion,
by disorder
Disorder Factor group
Risk/Protective
factor K N Measure ES (95% CI) p
PI
sign. I2
ET
sign.
ESB
sign.
LS
sign. eOR Class
Class
(-n > 1000)
Class
(-n > 1000,
prosp.)
Specific
phobia
Socio-demographic Male gender 9 689 OR 0.43 (0.36–0..51) <0.000001 Yes 0% No No Yes 0.43 IV I NA
Personality
dimensions
Neuroticism 1 79 g 0.81 (0.57–1.05) <0.000001 NA NA NA No Yes 4.35 IV II II
SAD Psychopathology Dysthymia 1 52 IRR 14.81 (6.7–32.73) <0.000001 NA NA NA No Yes 14.81 IV II II
Major depression 1 52 IRR 9.35 (4.71–18.54) <0.000001 NA NA NA No Yes 9.35 IV II II
Personality
dimensions
Neuroticism 1 89 g 0.89 (0.67–1.12) <0.000001 NA NA NA No Yes 5.02 IV II II
Life events Early emotional
trauma
3 720 OR 2.8 (1.84–4.24) 0.000001 No 36% No No Yes 2.80 IV III III
Early physical
trauma
4 1191 OR 2.59 (2.17–3.1) <0.000001 Yes 0 No No Yes 2.59 I I IV
Early sexual
trauma
5 1239 OR 3.18 (1.73–5.86) 0.00019 No 85% No No Yes 3.18 III III IV
Parental rearing
styles/attachment
Insecure
attachment in
childhood
1 76 g 1.26 (0.91–1.61) <0.000001 NA NA NA No Yes 9.83 IV II NA
Other Behavioral
inhibition in
childhooda
7 257 OR 7.52 (3.04–18.61) 0.000013 No 78% No Yes Yes 7.52 IV III III
GAD Socio-demographic Age (30 to 54) 1 390 OR 2.92 (1.78–4.78) 0.000022 NA NA NA No Yes 2.92 IV III III
Male gender 15 999 OR 0.5 (0.41–0.59) <0.000001 Yes 0% No No Yes 0.5 IV I NA
Psychopathology Bipolar I disorder 1 390 OR 2.58 (1.48–4.49) 0.00081 NA NA NA No Yes 2.58 IV III III
Borderline
personality
disorder
1 390 OR 4.71 (2.93–7.57) <0.000001 NA NA NA No Yes 4.71 IV II II
History of one
psychological
disorder
1 288 OR 1.7 (1.27–2.26) 0.00029 NA NA NA No Yes 1.70 IV III III
Internalizing
disorder at age 16
1 288 OR 2.01 (1.34–3) 0.00065 NA NA NA No Yes 2.01 IV III III
Internalizing
disorder at age 7
1 288 OR 1.91 (1.31–2.79) 0.00081 NA NA NA No Yes 1.91 IV III III
Narcissistic
personality
disorder
1 390 OR 2.31 (1.49–3.6) 0.00019 NA NA NA No Yes 2.31 IV III III
(Continued )
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Table 3. (Continued.)
Disorder Factor group
Risk/Protective
factor K N Measure ES (95% CI) p
PI
sign. I2
ET
sign.
ESB
sign.
LS
sign. eOR Class
Class
(-n > 1000)
Class
(-n > 1000,
prosp.)
Psychological
malaise at age 33
1 288 OR 4.73 (3.43–6.52) <0.000001 NA NA NA No Yes 4.73 IV II II
Schizotypal
personality
disorder
1 390 OR 2.6 (1.52–4.44) 0.00045 NA NA NA No Yes 2.60 IV III III
Subsyndromal
depression no
distress
1 563 OR 2.25 (1.56–3.24) 0.000014 NA NA NA No Yes 2.25 IV III III
Parental
psychopathology
Anxiety 8 254 OR 3.45 (1.97–6.02) 0.000013 Yes 0% No No Yes 3.45 IV III NA
GAD without
comorbidity
1 106 HR 3.77 (2.27–6.26) <0.000001 NA NA NA No Yes 3.77 IV II II
Major depression
in both parents
1 65 OR 3.7 (2.01–6.79) 0.000024 NA NA NA No Yes 3.70 IV III III
Major depression
in one parent
1 79 OR 2.51 (1.47–4.29) 0.00074 NA NA NA No Yes 2.51 IV III III
Personality
dimensions
Behavioral
inhibitiona
1 106 HR 1.97 (1.66–2.33) <0.000001 NA NA NA No Yes 1.97 IV II II
Harm avoidance 1 106 HR 1.69 (1.37–2.09) 0.000001 NA NA NA No Yes 1.69 IV III III
Substance use Cannabis use 1 83 OR 2.79 (1.55–5.02) 0.00059 NA NA NA No Yes 2.79 IV III III
Life events Early physical
trauma
1 350 OR 2.39 (1.92–2.98) <0.000001 NA NA NA No Yes 2.39 IV II NA
Early sexual
trauma
1 350 OR 3.28 (2.6–4.14) <0.000001 NA NA NA No Yes 3.28 IV II NA
Physical abuse in
childhood
1 165 OR 1.82 (1.33–2.48) 0.00017 NA NA NA No Yes 1.82 IV III IV
Separation events
in childhood
1 106 HR 2.44 (1.54–3.85) 0.00013 NA NA NA No Yes 2.44 IV III IV
Other Received mental
health treatment
from 20 to 32
1 52 OR 6.15 (2.81–13.45) 0.000005 NA NA NA No Yes 6.15 IV III III
Received
psychiatric
medication from
20 to 32
1 52 OR 5.19 (1.98–13.55) 0.00078 NA NA NA No Yes 5.19 IV III III
PD Socio-demographic Male gender 11 439 OR 0.5 (0.39–0.64) <0.000001 Yes 0% No No Yes 0.5 IV I NA
Psychopathology Major depression 2 771 OR 2.03 (1.66–2.49) <0.000001 NA 0% NA No Yes 2.03 IV II II
Panic attacks 1 811 OR 2.73 (1.93–3.88) <0.000001 NA NA NA No Yes 2.73 IV II II
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Post-traumatic
stress disorder
1 224 OR 2.59 (1.5–4.47) 0.00062 NA NA NA No yYes 2.59 IV III III
Separation anxiety
in childhood
10 880 OR 6.11 (4.31–8.66) <0.000001 Yes 5% No No Yes 6.11 IV I NA
Parental
psychopathology
Panic attacks (for
PDA)
1 54 OR 3.93 (1.91–8.07) 0.00019 NA NA NA No Yes 3.93 IV III III
Substance use Cigarette smoking
(daily)
2 201 HR 3.46 (2.21–5.41) <0.000001 NA 21% NA No Yes 3.46 IV II II
Cigarette smoking
(persistence in
daily smokers)
1 51 HR 14.46 (4.81.–43.5) 0.000002 NA NA NA No Yes 14.46 IV III III
Cigarette smoking
(persistence in
prior daily
smokers)
1 149 HR 3.18 (1.99–5.1) 0.000001 NA NA NA No Yes 3.18 IV III III
Life events Early emotional
trauma
1 123 OR 2.71 (1.57–4.68) 0.00035 NA NA NA No Yes 2.71 IV III NA
Early trauma 2 194 OR 3.56 (1.86–6.8) 0.00012 NA 0 NA No Yes 3.56 IV III NA
Early physical
trauma
4 449 OR 2.46 (1.95–3.11) <0.000001 Yes 0% No No Yes 2.46 IV I III
Early sexual
trauma
5 518 OR 2.91 (1.67–5.08) 0.00017 No 73% No No Yes 2.91 IV III III
Other Joint
hypermobility
syndrome
1 14 RR 22.34 (5.3–94.29) 0.000023 NA NA NA No Yes 22.34 IV III III
OCD Socio-demographic Paternal age >35 1 122 OR 5.34 (2.15–13.27) 0.00030 NA NA NA No Yes 5.34 IV III NA
Perinatal
complications
Ear infection 1 68 OR 57.81 (7.59–440.61) 0.00009 NA NA NA No Yes 57.81 IV III NA
Early
developmental
problems
1 13 OR 11.53 (2.84–46.78) 0.00062 NA NA NA No Yes 11.53 IV III NA
Excess weight gain
in pregnancy
1 68 OR 9.31 (2.62–33.1) 0.00057 NA NA NA No Yes 9.31 IV III NA
Hyperemesis 1 68 OR 8 (3.21–19.97) 0.000008 NA NA NA No Yes 8.00 IV III NA
Medication during
pregnancy
1 68 OR 5.45 (2.6–11.45) 0.000007 NA NA NA No Yes 5.45 IV III NA
Mumps 1 68 OR 11.41 (3.23–40.28) 0.00015 NA NA NA No Yes 11.41 IV III NA
Other postnatal
problems
1 68 OR 5.81 (2.04–16.52) 0.00096 NA NA NA No Yes 5.81 IV III NA
Other problems in
pregnancy
1 68 OR 12.18 (3.46–42.9) 0.0001 NA NA NA No Yes 12.18 IV III NA
Throat infection 1 68 OR 4.7 (2.28–9.7) 0.000028 NA NA NA No Yes 4.70 IV III NA
(Continued )
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Table 3. (Continued.)
Disorder Factor group
Risk/Protective
factor K N Measure ES (95% CI) p
PI
sign. I2
ET
sign.
ESB
sign.
LS
sign. eOR Class
Class
(-n > 1000)
Class
(-n > 1000,
prosp.)
Substance use Alcohol use
disorder
1 105 RR 2.41 (1.6–3.62) 0.000024 NA NA NA No Yes 2.41 IV III III
Use of cocaine and
others (no
marijuana)
1 105 RR 5.92 (4.97–7.05) <0.000001 NA NA NA No Yes 5.92 IV II II
Life events Emotional neglect
in childhood
1 74 g 0.75 (0.32–1.18) 0.00066 NA NA NA No Yes 3.90 IV III NA
History of verbal
abuse in family
1 33 OR 4.36 (1.88–10.11) 0.00061 NA NA NA No Yes 4.36 IV III NA
Sexual assault in
childhood
2 32 RR 4.03 (1.83–8.87) 0.00052 NA 0 NA No Yes 4.03 IV III NA
Personality
dimensions
Neuroticism 1 62 g 1.23 (0.96–1.5) <0.000001 NA NA NA No Yes 9.31 IV II II
Parental rearing
styles/attachment
Interference from
father
1 94 g 0.85 (0.55–1.14) <0.000001 NA NA NA No Yes 4.67 IV II NA
Overprotection
from father
6 716 g 0.44 (0.21–0.68) 0.00017 No 65% No No Yes 2.24 III III NA
Punishment from
father
1 94 g 0.71 (0.42–1) 0.000001 NA NA NA No Yes 3.62 IV III NA
Refusal from father 1 94 g 1.28 (0.98–1.59) <0.000001 NA NA NA No Yes 10.19 IV II NA
Warmth from
father
3 248 g −0.64 (−0.87 to
−0.42)
<0.000001 No 23% No No Yes 0.31 IV II NA
Other Postpartum 1 29 OR 12.05 (3.5–41.52) 0.000081 NA NA NA No Yes 12.05 IV III NA
Class, class of evidence, Class (−n > 1000)- class of evidence after removing the n > 1000 cases criterion, Class (−n > 1000, prosp.)– class of evidence after removing the n > 1000 cases criterion and after sensitivity analyses (including only prospective
studies); CI, confidence interval; ES, effect size; ET, Egger test; eOR, equivalent odds ratio; ESB, excess significance bias; g, Hedge’s g; GAD, generalized anxiety disorder; HR, hazard ratio; I2, heterogeneity; IRR, incidence rate ratio; K, number of studies
for each factor; LS, largest study with significant effect; N, number of cases; NA, not assessable; ns, not significant; OCD, obsessive-compulsive disorder; OR, odds ratio; PD, panic disorder; PDA, panic disorder with agoraphobia; PI, prediction interval;
SAD, social anxiety disorder; sign., significant; RR, relative risk.
a‘Behavioral inhibition’ referred to ‘the chronic tendency to respond to novel persons, places, and objects with wariness or avoidant behaviours’ in one meta-analysis (Clauss and Blackford, 2012) and to a personality/character dimension referring to
‘consistent restraint in response to social and non social situations’ in one systematic review (Moreno-Peral et al., 2014).
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Fig. 2. Forest plots of risk (in red) and protective (in green)
factors showing convincing (class I) or highly suggestive
(class II) evidence of association with each disorder, after
removing the n > 1000 cases criterion.
Psychological Medicine 11
Fig. 3. Forest plots of risk/protective factors assessed
in at least four of the disorders under study and show-
ing convincing (class I) or highly suggestive (class II)
evidence of association with at least one of the disor-
ders, after removing the n > 1000 cases criterion.
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unmeasured familial confounders (D’Onofrio et al., 2013) and
should improve the confidence in the identification of ‘non-purely
genetic’ risk/protective factors that are in the causal pathway for
anxiety and obsessive-compulsive disorders. For example, recent
population-based work in OCD has confirmed that a range of
perinatal complications are robustly associated with the disorder,
even after strict control of unmeasured genetic and environmental
confounders, and that the number of perinatal complications
cumulatively contribute to risk for the disorder (Brander et al.,
2016b). Similarly, as the field of psychiatric genetics is clearly
shifting away from the candidate gene approach into the less arbi-
trary genome-wide association studies (GWAS) approach, the
identification of genetic variants implicated in these disorders
should increase dramatically in the next few years, as exemplified
by the recent formation of an anxiety disorders group within the
psychiatric genetics consortium (Sullivan et al., 2018).
We also note that we identified very few protective factors that
were not reciprocal to risk factors. This indicates that most
research so far has focused on adverse/negative factors, and high-
lights another important aspect that will need to be addressed in
future studies.
Our results may also offer opportunities for prevention.
Current prevention programs for anxiety disorders have shown
modest benefits (Moreno-Peral et al., 2017) and there is a need
for new strategies. Our findings lend support to identifying
those individuals with several risk factors for inclusion in preven-
tion programs (Blanco et al., 2014). Large sets of risk factors of
small effects seem to account for the risk for anxiety and
obsessive-compulsive disorders, and therefore interventions that
try to modulate several of them concurrently should be devised.
For example, parental psychopathology and parental rearing styles
were significant risk factors for several of the disorders investi-
gated here and could be a combined target for prevention efforts.
Recent data on moderators and mediators of prevention strategies
should help optimise such efforts (Ginsburg et al., 2015). Our
results also support focusing on those modifiable risk factors
with the largest effects (e.g. trauma), and whose reduction
would have a greater prospective impact (Li et al., 2016).
Claims of success should await the results of randomized trials,
since observational associations may not necessarily represent
causal effects.
Our study has several strengths. We used systematic search
methods and both the study selection and data extraction were
conducted by independent raters. Moreover, we assessed that
each individual study included in the systematic review or
meta-analysis fulfilled our inclusion criteria and used standard
approaches to assess the methodological quality of the systematic
reviews or meta-analysis (Fusar-Poli and Radua, 2018). We offer
as online Supplementary material all data collected in our
umbrella review. Beyond encouraging open science, this databank
may contribute to the creation of a database of risk/protective fac-
tors for anxiety and obsessive-compulsive disorders that can be
updated in the future. We also note several limitations. First, we
assessed each of disorders separately and did not use a mixed
‘anxiety disorders’ category as an outcome. There have been
changes in the specific disorders included under the ‘anxiety dis-
orders’ category, complicating the interpretation of such analyses.
Second, we collected only information about factors assessed in
systematic reviews and meta-analyses, and studies not included
in this type of publication were not eligible for inclusion.
Moreover, not all factors were evaluated for all the disorders.
Third, we did not assess the quality of the individual studies
included in the systematic reviews and meta-analyses (because
this is beyond the scope of an umbrella review). Moreover,
there may be differences across-studies in the exact definitions
and methods of assessment for each factor. Finally, the almost
ubiquitously limited amount of evidence made us explore also
what would happen if we removed the need for >1000 cases to
have highly suggestive evidence. Nevertheless, great caution is
needed in trusting associations, no matter how strong and consist-
ent, where data are sparse.
In summary, we found a number of nominally statistically sig-
nificant risk and protective factors for anxiety and obsessive-
compulsive disorders, although very few were supported by robust
evidence. The limited amount of evidence was the main restrict-
ing factor, and this means that there is plenty of room to improve
the standards of evidence in this field. Our findings may help
optimize current prediction models and may provide hints for
testing prevention strategies.
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